ModifiedUnitedHealthcarePolicy MMP373.33

Urogenital/Anogenital (UG/AG) Panels

Coverage and clinical criteria for molecular syndromic (panel) testing of urogenital/anogenital infectious pathogens for UnitedHealthcare Medicare Advantage members; affects ordering clinicians and laboratories performing UG/AG CIDT panel testing.

Policy Summary

PayerUnitedHealthcare

PolicyUrogenital/Anogenital (UG/AG) Panels

Policy CodePolicy MMP373.33

Change TypeAdded/updated applicable ICD-10 diagnosis codesarchived prior version

Effective DateNov 1, 2025

Next Review Date

Key ActionDocument and retain clinical justification showing symptomatic presentation or high-risk exposure when ordering UG/AG panel testing and follow MolDx billing guidance and any delegate prior authorization requirements.

SourceLink

POLICY UPDATE CHANGES

Added ICD-10 diagnosis codes O09.90, O09.91, O09.92, O09.93, R10.20, R10.21, R10.22, R10.23, R10.24, R10.8A3, Z34.00, Z34.01, Z34.02, Z34.03, Z34.80, Z34.81, Z34.82, Z34.83, Z34.90, Z34.91, Z34.92, and Z34.93 to Applicable Codes.

Added notation that ICD-10 diagnosis code R10.2 was deleted September 30, 2025.

Archived previous policy version MMP373.32.

No NCDCMS NCD

MultipleLCDs apply

ExtensiveCodes provided

>=93%Sensitivity

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

54.3%Prevalence study

Coverage Criteria and Rationale

Coverage Rationale / When Panels are considered reasonable and necessary

Covered when ANY of the following conditions apply:

Epidemiologic indication or high-risk exposure: Epidemiologic indication or potential exposure to sexually transmitted pathogens (high-risk experience) is considered reasonable and necessary for urogenital/anogenital (UG/AG) molecular panel testing even in the absence of symptoms; the high-risk reason must be clearly documented.

Supports asymptomatic high-risk screening via panel when documented.

Targeted testing for specific clinical concern: When the primary clinical concern is for a few specific pathogens based on signs/symptoms (e.g., lesions suggestive of herpes simplex virus), only a small targeted panel (e.g., HSV-1 and HSV-2) is expected; expanded panels are not considered reasonable and necessary and will not be covered.

Expanded panels denied in this scenario.

Diagnosis of vaginosis/vaginitis: For diagnosis of infectious vaginosis/vaginitis, it is reasonable and necessary to perform a targeted or expanded panel that includes a combination of at least two of the following: Gardnerella vaginalis, other bacterial vaginosis–associated bacteria (such as Atopobium vaginae and/or Megasphaera types), Trichomonas vaginalis, and Candida species.at least 2 organisms included

Panel must include ≥2 specified organisms to be reasonable for vaginosis/vaginitis.

Clinical use and interpretation

Covered when testing is ordered with appropriate clinical indication and documentation supporting the diagnostic need in symptomatic patients or when coinfection evaluation is clinically warranted.

Clinical indication and documentation: Testing is intended for patients with signs or symptoms of vaginitis/vaginosis or when evaluation for co-occurring STIs is clinically indicated; results must be correlated with the clinical presentation because molecular tests may detect colonization rather than active infection.

Supported by statements on need for clinical correlation and study populations including symptomatic individuals.

Sample types validated: Assays have been validated on clinician-collected and self-collected vaginal swabs and, for some targets/assays, on urine or endocervical samples; specimen type used should match the assay's validated specimen types.

See MVP and other assay performance descriptions for specimen validation.

Assay performance considerations: Assays cited demonstrate high sensitivity and specificity for multiple targets, but performance varies by pathogen and assay; providers and laboratories should select assays with demonstrated performance for intended specimen types and interpret results in clinical context.

Evidence and clinical utility (informational)

Clinical utility and evidence summary (informational for coverage decisions):

Clinical utility summary: Molecular panel tests can detect pathogens not found by conventional methods; positive molecular detections may represent colonization rather than active infection and therefore require clinical correlation to determine management impact.

Supports use when detection would change patient management.

Evidence of high co-infection prevalence: Multiple studies report substantial rates of co-infection among patients tested for STIs and vaginitis, supporting multiplex testing from a single sample in contexts where co-infection evaluation would affect management.

Examples include 79.4% STI/BV co-infection (BD MAX study), 54.3% positivity for ≥1 pathogen in a 65,191-sample prevalence study, and 43.9% coinfection in an HPV-genotyped cohort.

Regulatory context: Several commercial nucleic acid–based multiplex assays have FDA 510(k) clearance; FDA status is informational and is not, by itself, a basis for coverage decisions.

Examples: Aptima BV Assay, BD MAX Vaginal Panel, Xpert Xpress MVP.

Expanded urogenital/anogenital (UG/AG) syndromic molecular panels are not considered reasonable and necessary and will not be covered when the clinical concern is limited to a few specific pathogens. In situations where signs or symptoms point to a small number of targets (for example, lesions suggestive of herpes simplex virus), clinicians are expected to order a targeted panel (e.g., HSV‑1 and HSV‑2) rather than an expanded syndromic panel.

Detection of pathogen nucleic acid by a molecular assay alone does not always indicate active infection. The policy notes that positive molecular results may represent colonization rather than current active infection, and therefore positive detections require correlation with the patient’s clinical presentation and documented rationale for testing.

Information about FDA 510(k) clearance for commercial NAAT panels is provided for context only. The policy states that FDA approval/clearance is informational and is not, by itself, a basis for coverage.

When clinical concern is limited to a small set of pathogens based on presenting signs or symptoms, use of an expanded syndromic panel is inappropriate. The policy explicitly indicates that use of expanded panels in cases where targeted testing is clinically appropriate is not medically necessary, and clinicians should perform focused testing for the suspected pathogens.

The policy does not support routine multiplex panel testing in asymptomatic individuals unless there is a clearly documented high‑risk epidemiologic indication or potential exposure. For asymptomatic testing to be considered reasonable and necessary, the high‑risk reason must be clearly documented in the medical record.

Positive molecular detections from syndromic panels must be interpreted in clinical context because they may reflect colonization rather than active disease. The policy emphasizes that clinical correlation is required before equating detection with active infection or initiating targeted therapy.

Indications Considered Reasonable and Necessary

Epidemiologic indication or documented high-risk exposure to STIs, including asymptomatic members

High-risk exposure documented: Epidemiologic indication or documented high-risk exposure to sexually transmitted infections (STIs), including asymptomatic members, is a covered indication for UG/AG panel testing when the high-risk reason is clearly documented in the medical record.

Documentation of the high-risk exposure must be present to support testing.

Diagnosis of infectious vaginosis/vaginitis when panel includes at least two specified organisms (Gardnerella, BVAB/Atopobium/Megasphaera, Trichomonas, Candida)

Vaginosis/vaginitis organism requirement: Diagnosis of infectious vaginosis or vaginitis is a covered indication when the panel includes at least two of the following organisms: Gardnerella vaginalis; other BV-associated bacteria (e.g., Atopobium vaginae, Megasphaera types); Trichomonas vaginalis; or Candida species.at least 2 organisms included

Panel must include ≥2 specified organisms to be considered reasonable and necessary for this indication.

Not Covered Indications and Clarifications

Expanded UG/AG panels performed when only a few pathogens are suspected are specifically identified as not covered. In scenarios where the primary clinical concern is limited (for example, suspicion confined to HSV), only a small targeted panel is expected and broader syndromic testing will be denied.

This segment of the policy does not list specific test names or categorical exclusions beyond the clinical correlation and medical‑necessity guidance. Instead, it reiterates that coverage decisions depend on appropriate clinical indication and documentation, and that a positive molecular result without supportive clinical findings may not meet medical‑necessity criteria.

FDA 510(k) clearance status for commercial assays is noted in the document for informational purposes only. The policy clarifies that FDA clearance alone does not guarantee coverage and should not be used as the sole justification for payment.

Coding and Applicable Codes

Panel CPT/HCPCS (listed)CPT

0352U	Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis-associated bacteria (BVAB-2, Atopobium vaginae, and Megasphera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis, vaginal-fluid specimen, each result reported as detected or not detected (Deleted 12/31/2024 - see CPT code 81515).
81513	Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis.
81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L. crispatus and L. jensenii), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and/or Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata, Candida krusei, when reported.
81515	Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers for Atopobium vaginae, Atopobium species, Megasphaera type 1, and Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), utilizing vaginal-fluid specimens, algorithm reported as positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and Candida species (Effective 01/01/2025).

ICD-10 Diagnosis Codes referencedICD-10

A51.0	Primary genital syphilis.
A54.00	Gonococcal infection of lower genitourinary tract, unspecified.
A56.00	Chlamydial infection of lower genitourinary tract, unspecified.
A59.00	Urogenital trichomoniasis, unspecified.
A60.00	Herpesviral infection of urogenital system, unspecified.
B37.31	Acute candidiasis of vulva and vagina.
Z11.3	Encounter for screening for infections with a predominantly sexual mode of transmission.
Z20.2	Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission.
Z72.51	High risk heterosexual behavior.

Referenced MolDx billing/coding guidancemixed

MolDX/L-codes referenced

Palmetto MolDx local L- and A- documents and MolDX program guidance (see listed entries L36021, A56973, etc.)

Added/Updated Applicable ICD-10 Diagnosis CodesICD-10

O09.90	Unspecified pregnancy, unspecified trimester
O09.91	High-risk pregnancy, first trimester
O09.92	High-risk pregnancy, second trimester
O09.93	High-risk pregnancy, third trimester
R10.20	Pelvic and perineal pain, unspecified (note: R10.2 deleted Sep. 30, 2025)
R10.21	Acute pelvic pain
R10.22	Chronic pelvic pain
R10.23	Pelvic and perineal pain during pregnancy
R10.24	Pelvic and perineal pain postpartum
R10.8A3	Other specified abdominal pain

1–10 of 22

1/3

FDA-cleared commercial assays (informational)mixed

Aptima BV Assay	Commercial NAAT for bacterial vaginosis (proprietary test name)
BD MAX Vaginal Panel	Commercial multiplex molecular panel for vaginitis/vaginosis pathogens
Xpert Xpress MVP	Commercial multiplex molecular panel for genitourinary pathogens

inv-15: positive percent agreement — reported sensitivity ranges for selected targets

Positive percent agreement (range)93.6% - 99% (reported for Xpert Xpress MVP vs comparators in prospective multicenter study)

Negative percent agreement (range)92.1% - 99.8% (reported for Xpert Xpress MVP; complementary specificity data)

BD MAX Vaginal Panel performance examplesBV 89.8% sensitivity / 96.5% specificity; VVC 97.4% / 96.8%; TV 100% / 100% (selected study results)

inv-16: Coinfection prevalence thresholds reported — high co-infection rates cited in evidence

High STI/BV co-infection rate79.4% STI/BV co-infection reported in BD MAX Vaginal Panel remnant-sample study (Van Der Pol et al., 2025)

Provider Actions, Documentation, and Billing

Billing Rule

Billing and laboratory certification references

Related Medicare Advantage reimbursement and CLIA laboratory certification requirements apply. Providers must follow UnitedHealthcare Medicare Advantage reimbursement policies and the CLIA ID Requirement Policy for laboratory certification when billing for molecular syndromic or expanded UG/AG panels.

Ensure the performing laboratory holds the appropriate CLIA certificate and report the CLIA ID on claims when required.
Follow UnitedHealthcare Medicare Advantage laboratory reimbursement and billing guidance for professional and facility claims.

Billing Rule

MolDx-guided coding and clinical justification

Follow MolDx (Palmetto GBA) coding and clinical justification guidance when applicable. Use MolDx-listed test codes and provide clinical documentation demonstrating medical necessity per MolDx requirements.

If a test is subject to MolDx review, supply the Molecular Diagnostic Test (MDT) identifier and supporting clinical information as requested by MolDx.

Ordering and Specimen Requirements

Billing Rule

Ordering and billing — follow UnitedHealthcare reimbursement and CLIA ID policies

Ordering providers and billing entities should follow UnitedHealthcare laboratory and molecular pathology reimbursement policies and ensure the performing laboratory's CLIA ID is used per the CLIA ID Requirement Policy.

Use the CLIA ID and facility billing guidance required by UnitedHealthcare policies when submitting claims.
Refer to the Clinical Laboratory Improvement Amendments (CLIA) ID Requirement Policy for professional billing specifics.

Documentation Required

Order panels only with documented symptoms/rationale and validated specimen type

Have documentation of signs/symptoms or clinical rationale for multiplex testing and order assays only for specimen types validated by the assay (e.g., clinician- or self-collected vaginal swabs, urine, endocervical swabs as applicable).

Confirm the assay's validated specimen types before ordering and document the specimen collected.
Record the patient's symptoms or other clinical rationale that justify use of a multiplex panel.

Frequency Limits

inv-43: FREQUENCY LIMITS — None specified in this section

Frequency limits specifiedNone specified in this section

Policy noteNo test- or member-specific repeat frequency or time-period limitations are provided in the Frequency Limits section of this document

Related guidanceOrdering and billing should follow UnitedHealthcare laboratory and molecular pathology reimbursement policies and CLIA ID requirements (see related policies)

inv-44: FREQUENCY LIMITS — Molecular syndromic panels frequency not specified

Molecular syndromic panels frequencyNot specified — the policy does not define repeat testing intervals for molecular syndromic panels

Assay-specific validationFrequency and repeat testing considerations should align with assay validation and clinical context (e.g., symptomatic evaluation vs epidemiologic screening)

Definitions and Test Descriptions

inv-30: Panel — A test that detects > 1 pathogen

Panel (definition)A test that detects > 1 pathogen.

Typical useUsed to detect multiple infectious agents from a single specimen when clinical symptoms overlap

ScopeApplies to urogenital/anogenital molecular panel testing described in the policy

inv-31: Syndromic Panel definition — detects multiple pathogens associated with overlapping symptoms

Syndromic Panel (definition)A test that simultaneously detects multiple different pathogens associated with similar and overlapping clinical symptomatology.

Clinical rationaleUseful when symptom overlap exists (e.g., vaginitis vs vaginosis vs STI) and co-infection evaluation may alter management

Background and Evidence Context

Syndromic molecular or culture‑independent diagnostic tests (CIDTs) detect multiple pathogens from a single urogenital or anogenital specimen and can shorten turnaround time compared with some conventional methods. These panels are particularly useful when overlapping symptoms make multiple pathogens possible and when a documented epidemiologic or high‑risk exposure exists; however, positive detections require clinical correlation to distinguish colonization from active infection.

inv-03 (supporting evidence): Evidence and clinical utility — clinical studies and validation cohorts cited (informational)

Supporting clinical studies, validation cohorts, and prevalence data (informational):

BD MAX Vaginal Panel study: Van Der Pol et al. evaluated the BD MAX Vaginal Panel in symptomatic remnant specimens and reported STI/BV co-infection rates (79.4%) and utility of identifying co-occurring infections from a single sample.

Demonstrates high co-infection prevalence supporting multiplex testing.

Xpert Xpress MVP clinical validation: Lillis et al. (MVP) prospective multicenter study of clinician- and self-collected vaginal swabs reported high positive percent agreement (93.6%–99%) and negative percent agreement (92.1%–99.8%) for MVP targets compared to comparators.

Revision History and Policy Changes

2025-11-01applicable_codes_updatedLatest

Policy Summary

PayerUnitedHealthcare

PolicyUrogenital/Anogenital (UG/AG) Panels

Policy CodePolicy MMP373.33

Change TypeAdded/updated applicable ICD-10 diagnosis codesarchived prior version

Effective DateNov 1, 2025

Next Review Date

SourceLink

On This Page

Performance ranges and study limitations described in assay validation studies.

Symptomatic vaginitis/vaginosis testing and detection of co-occurring STIs (CT/GC/TV) where clinical management may be impacted

Symptomatic presentation and impact on management: Testing is covered for symptomatic patients with vaginitis/vaginosis when evaluation for co-occurring STIs (e.g., Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis) may impact clinical management; clinical correlation is required.

Supported by clinical validation studies enrolling symptomatic individuals and by data demonstrating STI co-infection rates in symptomatic cohorts.

Detection of pathogens in symptomatic patients evaluated for vaginitis, vaginosis, or STIs, and detection of co-infections from a single urogenital/vaginal specimen

Single-specimen detection of co-infections: Detection of pathogens and co-infections from a single urogenital or vaginal specimen is covered for symptomatic patients evaluated for vaginitis, vaginosis, or sexually transmitted infections when identification of co-occurring infections may inform management; positive results must be interpreted with clinical correlation.

Studies demonstrate high rates of co-infection and utility of single-sample multiplex testing for identifying concurrent infections.

Percent positive for ≥1 pathogen in large prevalence study54.3% positivity for one or more sexually transmitted pathogens in 65,191-sample Korean study (Lee et al., 2022)

Overall co-infection prevalence examplesOther cohort reports include overall coinfection prevalence figures (e.g., 43.9% in HPV-genotyped cohort cited elsewhere in evidence summary)

Document the clinical indication, signs/symptoms, specimen source, and why multiplex/expanded testing is necessary versus targeted assays.

Denial Risk

Expanded UG/AG Panels will not be covered when primary concern is limited

Expanded urethritis/genital and anorectal-genital (UG/AG) multiplex panels will not be covered when the primary clinical concern is limited to a few specific pathogens with corresponding signs or symptoms. In those circumstances perform targeted testing for the pathogens of concern.

When clinical concern is limited (e.g., lesions suggestive of HSV), order a small targeted panel (e.g., HSV-1 and HSV-2) rather than an expanded UG/AG panel.
For asymptomatic testing, expanded panels are reasonable only when a documented high‑risk exposure or epidemiologic indication exists.

Documentation Required

Documentation and benefit limitations

Providers must retain clinical records and be prepared to provide documentation on request. Failure to retain or produce required documentation may jeopardize coverage or payment.

Keep copies of operative notes, laboratory requisitions, clinical visit notes, and any documentation of high‑risk exposure used to justify panel testing.
If documentation is requested during claim review or audit, provide timely and complete records to support medical necessity.

Documentation Required

Documentation of high-risk exposure

When a high‑risk epidemiologic exposure or potential exposure justifies UG/AG panel testing, the high‑risk reason must be clearly documented in the medical record.

Document the nature of the exposure, timing, and clinical context (e.g., known contact with a partner diagnosed with an STI, multiple recent partners, or other epidemiologic risk factors).
If testing is performed in the absence of symptoms solely because of a high‑risk exposure, include explicit documentation of that high‑risk experience in the chart.

Documentation Required

Clinical documentation to support testing

Clinical documentation must support the medical necessity of multiplex or expanded panel testing. Include signs, symptoms, specimen source, and rationale why broader multiplex testing is appropriate instead of targeted assays.

Record presenting signs and symptoms that suggest multiple possible pathogens (e.g., diffuse respiratory symptoms, systemic signs) when ordering broad panels.
Explain in the record why single‑pathogen testing would be insufficient or why results would change management.
Note that positive molecular findings may represent colonization; include clinical correlation in interpretation and follow‑up plans.

Billing Rule

Records and claims submission

Submit accurate claims and retain supporting documentation for audits or medical necessity reviews. For delegated plans, follow the delegate's utilization management and prior authorization requirements.

Report appropriate CPT/HCPCS/ICD-10 codes and include CLIA ID when required.
If the member's plan uses a delegated entity for prior authorization, comply with that delegate's submission and documentation processes.
Maintain documentation for the timeframe required by payer and regulatory policies to support claims and coverage decisions.

Prior Authorization

Follow member-specific benefits and delegate prior authorization processes

Providers must follow member-specific benefit documents and any delegated prior authorization processes; this policy is intended to guide coverage decisions but does not replace plan or delegate requirements.

Check the member's benefit plan for coverage specifics and any prior authorization requirements.
When a delegate manages prior authorization, obtain approval per the delegate's process prior to testing.

Provider responsibilitiesProviders must document clinical indication; member-specific benefit documents and delegate prior authorization rules may impose additional limits

inv-45: FREQUENCY LIMITS — placeholder / unspecified frequency limits

Frequency limits (unspecified)No frequency limits provided or defined in this document fragment

Placeholder noteThis entry is intentionally unspecified in the policy; refer to member benefit documents or utilization management delegates for any limits

Follow-up actionsIf frequency limits are required by plan or delegate, orderers should obtain prior authorization and document medical necessity

Sample typesTypical specimens include vaginal swabs, urine, and endocervical swabs depending on assay validation

inv-32: Analytical Validity (AV) definition

Analytical Validity (AV)Assessment of the test's technical performance (sensitivity, specificity, accuracy, precision).

PurposeDetermines whether the test measures what it was designed to measure; does not assess clinical usefulness

ComponentsIncludes measures such as limit of detection, reproducibility, and accuracy for intended specimen types

inv-33: Clinical Utility (CU) definition

Clinical Utility (CU)The ability of a test to provide information related to patient care and management and to inform treatment decisions.

Coverage focusCMS and payers assess whether use of the test guides management and improves health outcomes

Use caseRelevant when test results will change diagnosis, treatment, or patient monitoring

inv-34: Clinical Validity (CV) definition

Clinical Validity (CV)Ability of a test to classify a patient's circumstance into diagnostic, prognostic, or predictive categories and detect the disease of interest in the defined population.

VariabilityClinical validity is not a fixed value and may vary by population and specimen type

Relation to AV/CUCV differs from AV (technical performance) and CU (impact on care); all inform coverage decisions

inv-35: Molecular syndromic panel (NAAT/PCR-based) description

Molecular syndromic panel (description)A multiplex nucleic acid amplification test (NAAT/PCR-based) that simultaneously detects multiple infectious pathogens associated with a clinical syndrome (e.g., vaginitis/vaginosis).

AdvantagesProvides rapid turnaround and often greater sensitivity than traditional methods for multiple organisms

LimitationsPerformance characteristics vary by panel and pathogen; clinical correlation is required to interpret results

inv-36: Xpert Xpress MVP — qualitative automated PCR test description with <1 hour turnaround (definition/example)

Xpert Xpress MVP (example)A qualitative automated PCR test detecting DNA targets associated with BV, TV, and Candida species with results available in less than one hour (evaluated on clinician- and self-collected vaginal swabs).

Study contextProspective, multicenter, cross-sectional clinical study including symptomatic individuals; reported high positive percent agreement (93.6%–99%) vs comparators

Intended settingsDesigned for laboratory and point-of-care settings with untrained operator use possible

inv-37: Molecular panel tests — nucleic acid–based multiplex assays that detect multiple organisms from a single specimen

Molecular panel tests (general)Nucleic acid–based multiplex assays that detect multiple organisms (e.g., BV, Candida spp., GC, CT, TV) from a single vaginal or urogenital specimen.

Clinical impactCan detect pathogens missed by conventional methods and facilitate identification of coinfections from one specimen

VariabilityPerformance varies by assay and target; choose assays validated for the intended specimen type and clinical question

inv-38: Colonizer vs pathogen — detected organisms may represent colonization rather than active infection

Colonizer vs pathogen (interpretation)Detected organisms may represent colonization rather than active infection; positive molecular results require clinical correlation to determine significance.

Coverage implicationPositive detection alone may not establish medical necessity without documentation of clinical signs/symptoms or epidemiologic risk

Provider actionClinicians should interpret results in the context of symptoms, exam, and other diagnostic findings before initiating treatment

positive percent agreement 93.6%–99%

Assay performance evidence supports test accuracy for intended specimen types.

Aptima assays validation: Schwebke et al. prospective multicenter study of Aptima BV and CV/TV assays in symptomatic women demonstrated high sensitivity and specificity for BV, Candida, and TV compared to reference methods, and superior performance versus clinician diagnosis for BV.

Supports improved diagnostic performance of molecular assays over conventional clinical assessment for vaginosis/vaginitis.

Large prevalence studies: Lee et al. (65,191 samples) and Hernández-Rosas et al. reported substantial overall detection rates (e.g., 54.3% positivity for ≥1 pathogen and 43.9% coinfection prevalence in an HPV cohort), illustrating high background prevalence and potential for multiplex detection to identify clinically relevant co-infections.

Prevalence data inform contexts where multiplex testing may alter management.